Treatment management for BRAF -mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.
Maximilian HaistHenner StegeFriederike RogallYuqi TanImke von WasielewskiKai Christian KlespeFriedegund MeierPeter MohrKatharina C KählerMichael WeichenthalAxel HauschildDirk SchadendorfSelma UgurelGeorg LoddeLisa ZimmerRalf GutzmerDirk DebusBastian SchillingAlexander KreuterJens UlrichFrank MeissRudolf HerbstAndrea ForschnerUlrike LeiterClaudia PfoehlerMartin KaatzFabian ZillerJessica C HasselMichael TronnierMichael SachseEdgar DippelPatrick TerheydenCarola BerkingMarkus V HepptFelix KieckerSebastian HaferkampChristoffer GebhardtJan Christoph SimonStephan GrabbeCarmen LoquaiPublished in: Journal for immunotherapy of cancer (2023)
mut melanoma patients who developed DM upon upfront adjuvant therapy achieve favorable tumor control and prolonged PFS after switching treatment modalities in the first-line setting of stage IV disease. Patients with locoregional recurrence benefit from complete resection of recurrence followed by a second adjuvant treatment with TT.